Month: August 2024

Camposol Holding PLC will announce its financial results for the second quarter of 2024 on Tuesday, August 27, 2024, at 9:00 am Peru Time. In connection with this release, Ricardo Naranjo Fernandez, Interim CEO, and Jossue Yesquen Lihim, IRO, will host a conference call presentation and Q&A session. To register and participate in the conference call please use the following link: https://register.vevent.com/register/BI1bc604722f9e4fd4967238968ea1a03a Participants are advised to log in to the conference call service and check their settings a few minutes before the conference call begins. To access the webcast presentation associated with the conference call, please use the following link: https://edge.media-server.com/mmc/p/6ktizsuy If you are unable to participate in the conference call, a playback of the conference will be available...

MONTREAL, Aug. 05, 2024 (GLOBE NEWSWIRE) — Senvest Capital Inc. today reported a net loss attributable to common shareholders of ($71.7) million or ($29.02) per share for the three months ended June 30, 2024. This compares to net income attributable to common shareholders of $21.2 million or $8.58 per share for the same period in 2023. Financial statements are available online at Sedar+ www.sedarplus.ca  CONSOLIDATED STATEMENTS OF INCOME  (unaudited)  (in millions of dollars, except per share amounts)  For the three months ended  06/30/2024   06/30/2023       Net income (loss) attributable to           common shareholders ($71.7)     $21.2         Diluted earnings (loss) per share           attributable to common shareholders ($29.02)     $8.58             Contact: George Malikotsis, Vice...

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information:Date: Wednesday, August 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference: 39584Webcast Access: Click Here The conference call utilizes the “Call me™” technologyhttps://emportal.ink/3zo6zXz Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link, above, for instant...

Continued Operational Momentum Drives Year-Over-Year Profitability Improvement SPRINGDALE, Ark., Aug. 05, 2024 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) Third Quarter   Nine Months Ended    2024     2023       2024     2023  Sales $ 13,353   $ 13,140     $ 39,744   $ 39,533                 Operating Income (Loss) $ 341   $ (350 )   $ 884   $ 68  Adjusted1Operating Income (non-GAAP) $ 491   $ 179     $ 1,308   $ 697                 Net Income (Loss) Per Share Attributable to Tyson $ 0.54   $ (1.18 )   $ 1.25   $ (0.56 )Adjusted1Net Income (Loss)...

Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 Q2 2024 Adjusted EBITDA(1) of $137 million increased 7%, compared to Q2 2023 Q2 2024 Adjusted EPS(1) of $0.19 declined $0.01 per diluted share, compared to Adjusted EPS of $0.20 in Q2 2023 Successfully refinanced debt structure, extending debt maturities to 2031 Reaffirming 2024 outlookCLEVELAND, Aug. 05, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three and six months ended June 30, 2024. Second-quarter...

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. “The first half of 2024 has been outstanding for BioCryst due to the success we are having in the marketplace with ORLADEYO. As a result, we are increasing our full year guidance for ORLADEYO, advancing multiple programs toward the clinic in the next 18 months and moving the company closer to...